TICKERNERD
Menu
NAMSNAMSHealthcare · Biotechnology

NAMS Stock Forecast: NewAmsterdam Pharma Co. NV Price Predictions for 2026-2027

Last close, 14 Aug 2026
$27
+1.16% on the day

The 16 Wall Street analysts covering NewAmsterdam Pharma Co. NV hold a median 12-month price target of $52 — +93.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$3.2B
Ticker Nerd rank
41 / 100
Median analyst target
$52
Analysts covering
16
Total return, dividends reinvested
1W
−3.5%
1M
−19.0%
YTD
−23.1%
1Y
+7.2%
From 52W high
−34.9%
From 52W low
+12.7%
$24
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NAMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NewAmsterdam Pharma Co. NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
72
Value
70
Volatility
64
Momentum
56
Quality
53
Revisions
48
Issuance
34
Size
31
Growth
18

Accruals (72): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NAMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NAMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26NAMSHigh $60Median $52Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says16 analysts
15 Buy1 Hold0 Sell
Low $38Median $52High $60

The green dot is the last close — the median target sits +93.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026RBC CapitalMaintainsOutperform$51 → $50
30 June 2026RBC CapitalMaintainsOutperform$47 → $51
30 June 2026RBC CapitalMaintainsOutperform—
19 Feb 2026GuggenheimMaintainsBuy—
18 Feb 2026NeedhamMaintainsBuy—
21 Jan 2026RBC CapitalMaintainsOutperform—
16 Dec 2025StifelMaintainsBuy—
2 Dec 2025Goldman SachsMaintainsNeutral—
6 Nov 2025RBC CapitalMaintainsOutperform—
5 Nov 2025NeedhamMaintainsBuy—
20 Oct 2025HC Wainwright & Co.AssumesBuy$52
17 Oct 2025CitigroupMaintainsBuy—
25 Aug 2025Wells FargoInitiatesOverweight—
7 Aug 2025RBC CapitalMaintainsOutperform—
17 July 2025Goldman SachsInitiatesNeutral—
17 June 2025CitigroupInitiatesBuy—
12 June 2025NeedhamReiteratesBuy—
10 June 2025StifelInitiatesBuy—
8 May 2025NeedhamMaintainsBuy—
8 Apr 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NAMS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NAMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

NewAmsterdam Pharma Co. NV (NAMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.1×

Cheaper than 95% of US stocks

Price / sales
442.9×

Cheaper than 2% of US stocks

Price / book
5.0×

Cheaper than 22% of US stocks

EV / EBITDA
−10.6×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−80.7%

Higher than 3% of US stocks

Earnings growth (YoY)
−80.7%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−1752.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.8%

Higher than 25% of US stocks

Return on assets
−20.1%

Higher than 19% of US stocks

Dividend yield
2.4%

Higher than 55% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NAMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NAMSNewAmsterdam Pharma Co. NV$3.2B
41
IOVAIovance Biotherapeutics, Inc.$3.1B
90
IMNMImmunome, Inc.$3.0B
34
ALMSAlumis, Inc.$3.2B
51
CLDXCelldex Therapeutics, Inc.$3.2B
31
ARQTArcutis Biotherapeutics, Inc.$3.2B
89
MBXMBX Biosciences, Inc.$3.3B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NewAmsterdam Pharma Co. NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NAMS news & analysis

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

Seeking Alpha · 9 Aug 2026neutral

NewAmsterdam Pharma hosted an Analyst/Investor Day, and a transcript of the event was published by Seeking Alpha. The item indicates the company engaged with analysts and investors but provides no details on what was discussed.

Why it matters — A NAMS watcher would care because an investor day transcript can offer insights into management's updates and outlook presented to the analyst community.

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

MarketBeat · 5 Aug 2026positive

NewAmsterdam Pharma held its annual Investor Day, outlining its cardiovascular outcomes strategy for obicetrapib, providing updates on additional clinical programs, and discussing commercial preparations ahead of a potential European launch. The event comes as an interim readout from the PREVAIL trial nears.

Why it matters — A NAMS watcher would care because the Investor Day offers insight into the company's pipeline progress and commercial readiness for obicetrapib ahead of a possible European launch and the upcoming PREVAIL interim data.

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 5 Aug 2026negative

NewAmsterdam Pharma reported a Q2 loss of $0.52 per share, wider than the Zacks Consensus Estimate of a $0.48 loss. The company also lagged revenue estimates for the quarter.

Why it matters — NAMS watchers will note that the company's quarterly results missed analyst expectations on both earnings and revenue.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

GlobeNewsWire · 5 Aug 2026positive

NewAmsterdam Pharma reported Q2 2026 financial results and provided a corporate update, including a positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe, with $678.3 million in cash, cash equivalents and marketable securities as of June 30, 2026.

Why it matters — The positive CHMP opinion is a key regulatory milestone bringing obicetrapib closer to potential European market approval, which NAMS watchers would see as a significant step forward for the company's lead product candidate.

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

GlobeNewsWire · 29 July 2026neutral

NewAmsterdam Pharma announced it will hold an Investor Day for analysts and investors on August 5, 2026, in New York City, starting at 9:00 a.m. ET.

Why it matters — The Investor Day could provide updates on the company's pipeline and strategy for its oral, non-statin cardiovascular disease treatments, offering analysts and investors a deeper look at its clinical progress.

FAQ

Frequently asked questions about NAMS stock

What is the NAMS stock price forecast for 2026-2027?

The 16 Wall Street analysts covering NewAmsterdam Pharma Co. NV have a median 12-month price target of $52, with estimates ranging from $38 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NAMS stock a buy right now?

Of the 16 analysts covering NewAmsterdam Pharma Co. NV, 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NewAmsterdam Pharma Co. NV 41 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NAMS?

As at 15 Aug 2026, NewAmsterdam Pharma Co. NV ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (72 of 100).

Will NAMS stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +93.2% from the last close, and Ticker Nerd's factor model ranks NewAmsterdam Pharma Co. NV 41 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NAMS stock forecast for 2030?

No analyst covering NewAmsterdam Pharma Co. NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $60 over the next 12 months.

How has NAMS stock performed over the past year?

NewAmsterdam Pharma Co. NV returned +7.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NewAmsterdam Pharma Co. NV do?

NewAmsterdam Pharma Co. N.V.

What is the latest news on NAMS?

The most recent item we track (Seeking Alpha, 9 Aug 2026): "NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript". NewAmsterdam Pharma hosted an Analyst/Investor Day, and a transcript of the event was published by Seeking Alpha. The item indicates the company engaged with analysts and investors but provides no details on what was discussed.

Company

About NewAmsterdam Pharma Co. NV.

NewAmsterdam Pharma Co. N.V. is a pharmaceutical company focused on the research, development, and commercialization of transformative therapies addressing cardiovascular diseases. The company's primary mission is to innovate in the cardiovascular space by introducing medications that meet the evolving needs of patients worldwide. Notably, NewAmsterdam Pharma is at the forefront of developing novel treatments aimed at reducing cardiovascular risk and improving patient outcomes. Operating within the life sciences sector, the company leverages advanced scientific research and development capabilities to push forward its pipeline of projects. By concentrating specifically on cardiovascular therapies, NewAmsterdam Pharma aims to significantly impact a critical area of healthcare that affects millions globally. In the financial markets, the company represents an essential player within the pharmaceutical industry, focused on addressing unmet medical needs. Its work has substantial implications for both the healthcare sector and broader economic landscapes, illustrating the importance of continuous innovation in tackling global health challenges.

CEO Dr. Michael Harvey Davidson FACC, Facp., M.D. · 100 employees · Netherlands · https://www.newamsterdampharma.com